ESSA Pharma
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 50
- Market Cap
- $230.7M
- Introduction
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastatic castration-resistant prostate cancer
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Essa Pharma Inc.
- Target Recruit Count
- 50
- Registration Number
- 2023-509336-25-00
- Locations
- 🇪🇸
Hospital Clínic Barcelona, Barcelona, Spain
🇬🇧NEXT Madrid Hospital Quirónsalud Madrid, Madrid, United Kingdom
🇪🇸Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- ESSA Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT04421222
- Locations
- 🇺🇸
Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostatic NeoplasmsGenital Diseases, MaleProstatic DiseasesGenital Neoplasms, Male
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- ESSA Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT02606123
- Locations
- 🇺🇸
Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
News
ESSA Pharma Agrees to $1.91 Per Share Acquisition by XenoTherapeutics in Wind-Down Transaction
ESSA Pharma Inc. has entered into a definitive agreement to be acquired by XenoTherapeutics Inc. for approximately $1.91 per share in cash as the company discontinues operations and winds down its prostate cancer drug development business.
Tang Capital's Concentra Biosciences Acquires Elevation Oncology for $0.36 Per Share in Latest Biotech Liquidation
Elevation Oncology has agreed to be acquired by Concentra Biosciences, controlled by hedge fund Tang Capital Partners, for $0.36 per share in cash with additional contingent value rights.
ESSA Pharma Discontinues Masofaniten Trials, Initiates Strategic Review
ESSA Pharma has halted the clinical development of masofaniten after an interim analysis showed it was unlikely to meet the primary endpoint in combination with enzalutamide.
FDA Accepts Bayer's Nubeqa sNDA for Metastatic Hormone-Sensitive Prostate Cancer
The FDA has accepted Bayer's sNDA for Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for mHSPC.
ESSA Pharma Halts Masofaniten Development After Phase II Futility Analysis
ESSA Pharma discontinues development of masofaniten after a Phase II trial showed no significant benefit over enzalutamide alone in mCRPC patients.
ESSA Pharma Discontinues Phase II Masofaniten Trial for Prostate Cancer
ESSA Pharma halted its Phase II trial of masofaniten plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) due to interim analysis results.
ESSA Pharma Discontinues Phase 2 Trial of Masofaniten Plus Enzalutamide in mCRPC After Futility Analysis
ESSA Pharma halted a phase 2 trial of masofaniten plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) due to low likelihood of meeting the primary endpoint.
ESSA Pharma Discontinues Phase II Trial of Masofaniten in Prostate Cancer
ESSA Pharma halted its Phase II trial of masofaniten plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC) due to interim analysis results.
ESSA Pharma Halts Phase 2 Trial of Masofaniten Plus Enzalutamide in mCRPC
ESSA Pharma terminated a Phase 2 trial of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) due to futility analysis.
ESSA Pharma Halts Phase 2 Masofaniten Trial in Metastatic Castration-Resistant Prostate Cancer
ESSA Pharma terminated its Phase 2 trial of masofaniten plus enzalutamide for mCRPC after interim analysis showed no clear efficacy benefit over enzalutamide alone.